Study Finds No Advantage of Biomarker-Based Risk Scores in Personalizing Atrial Fibrillation Treatment
A recent study reveals that biomarker-based risk scores do not improve outcomes in personalized atrial fibrillation care compared to traditional guidelines, highlighting the need for further research in treatment customization.
Recent research presented at ESC Congress 2025 has concluded that using biomarker-based risk scores to tailor treatment strategies in patients with atrial fibrillation (AF) does not lead to improved clinical outcomes compared to standard guideline-based care. The study, a large registry-based randomized trial conducted across 39 Swedish sites, investigated whether incorporating biomarker scores like ABC-AF-stroke and ABC-AF-bleeding into treatment decisions would reduce the incidence of stroke and death.
Patients eligible for the trial included adults diagnosed with AF, regardless of whether they were on oral anticoagulant (OAC) therapy. Participants were randomized into two groups: a treatment arm guided by individual risk scores and recommendations, and a control group managed under usual clinical practice without biomarker data. Although the intervention successfully increased OAC use broadly, the primary outcome—composite of stroke or death—occurred at similar rates in both groups, around 3.2/100 patient-years.
The trial also found no significant differences in the rates of stroke, death, or major bleeding between the two arms over a median follow-up of 2.6 years. Despite the promising validation of these biomarker scores in previous studies, the results suggest that their implementation for personalized treatment did not provide additional benefit in this population. Notably, the trial was prematurely terminated due to safety concerns, and the event rates were lower than expected, leading to an underpowered study.
Lead researcher Professor Jonas Oldgren emphasized that further prospective testing is essential before integrating new risk stratification tools into routine AF management. Overall, this study underscores the importance of rigorous validation of precision medicine approaches and suggests that current standard care remains effective for stroke prevention in AF patients.
Source: https://medicalxpress.com/news/2025-09-benefit-biomarker-based-scores-personalize.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Gwada-negative: The Rarest Blood Group on Earth
French scientists have discovered the world's rarest blood group, Gwada-negative, found in a woman from Guadeloupe. This groundbreaking finding highlights the complexity of human blood systems and the potential for future personalized transfusion solutions.
Understanding the Brain's Hemispheric Division and Its Functional Significance
Explore how the human brain's hemispheric division helps optimize visual perception and cognitive functioning, revealing insights from recent MIT neuroscientific research.
Majority of NHS Staff Cite Improved Pay as Crucial for Retention
A new survey reveals that nearly two-thirds of NHS staff believe improved pay is essential to improve retention and address workforce shortages, amid ongoing pay disputes.
